Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers

Julia Remnestål(Science for Life Laboratory), Peter Nilsson(Science for Life Laboratory), Jennie Olofsson(Science for Life Laboratory), Anna Månberg(Science for Life Laboratory), Abbe Ullgren(Karolinska University Hospital), Linn Öijerstedt(Karolinska University Hospital), Mathias Uhlén(Science for Life Laboratory), Kim Kultima(Uppsala University), Sofia Bergström(Science for Life Laboratory), Martin Ingelsson(Uppsala University), Lena Kilander(British Geriatrics Society), Caroline Graff(Karolinska Institutet)
Translational Neurodegeneration
June 23, 2020
10.1186/s40035-020-00198-y
Cited by 71

Related Papers

Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
|Science|2005|2k
Defeating Alzheimer's disease and other dementias: a priority for European science and society
|The Lancet Neurology|2016|1.7k
The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide
|PLoS ONE|2010|1k
How many human proteoforms are there?
|Nature Chemical Biology|2018|945